Compare Abeona Therapeutics Inc (ABEO) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wolfspeed Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Wolfspeed Inc trades at $34.9 (market cap $1.87B). The key difference: Wolfspeed Inc is far larger — about 5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | WOLF | |
|---|---|---|
Market Cap | $373.32M | $1.87B |
Sector | Health | Technology |
52-Week High | $7.23 | $73.68 |
52-Week Low | $4.17 | $1.19 |
Enterprise Value | $228.22M | $2.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Wolfspeed (WOLF) trades at $39.47, down 1.33% today, amid bearish technical signals and negative profitability metrics. The company shows strategic progress with AI data center revenue growth and key partnerships, though it faces significant financial challenges with negative gross margins and net losses. Technical indicators show the stock testing support levels with overall bearish momentum despite some neutral oscillators.
The outlook remains cautious with Wall Street divided (31.58% buy ratings) amid ongoing losses and competitive pressures. Near-term catalysts include the Q2 2026 earnings report and execution on defense/aerospace partnerships, but investors face substantial risk from cash burn and market volatility in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
